Search
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Eluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalMarketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms … of both pain and diarrhea characteristic of IBS-D.
Categories: mu-Opioid Receptor AgonistVildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigational[L32803] Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy. … Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme.
Mixtures: GLIMETAL-DP, XILIARXS-DUOCanakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalCanakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are … Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP.
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label]. … These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label].
Mixtures: Fludalt DUO 250/50mcg Inhalation Powder Hard CapsulesCetyl alcohol
go.drugbank.com/drugs/DB09494ApprovedDue to its water-binding property, cetyl alcohol is commonly used as an emollient that prevents drying and chapping of the skin [A32209]. … It can be produced from the reduction of palmitic acid.
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product. … [L47042] Later, it was further approved as a combination product with [vilanterol] and [vilanterol]/[fluticasone furoate] under the brand name ANORO ELLIPTA and TRELEGY ELLIPTA respectively.
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488] … Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of [acetaminophen] overdose.
Mixtures: TUSSIFLEX DUO JARABE, N-ACETILCISTEÍNA MAS GUAYACOLATO DE GLICERILOProducts: ACETILCISTEINA DOC GENERICI